Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis: safety, efficacy, and patient acceptability

References

• MenterAKormanNElmetsCGuidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agentsJ Am Acad Dermatol200961345148519493586
   PubMed Web of Science ®Google Scholar
• CatherJMenterANovel therapies for psoriasisAm J Clin Dermatol20023315917311978137
   PubMedGoogle Scholar
• WeinsteinGDJeffesEWIIIMethotrexateKooJYLevinECLeonAWuJJGottliebABModerate to Severe Psoriasis4th edBoca Raton, FLCRC Press2014151168
   Google Scholar
• MedlinePlusMethotrexate [web page on the Internet]Bethesda, MDNational Institutes of Health United States National Library of Medicine nd [updated May 15, 2014]. Available from: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682019.htmlAccessed December 30, 2014
   Google Scholar
• GottliebAKormanNGordonKGuidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologicsJ Am Acad Dermatol200858585186418423261
   PubMed Web of Science ®Google Scholar
• KalbRStroberBWeinsteinGLebwohlMMethotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus ConferenceJ Am Acad Dermatol200960582483719389524
   PubMed Web of Science ®Google Scholar
• PincusTYaziciYSokkaTAletahaDSmolenJSMethotrexate as the “anchor drug” for the treatment of early rheumatoid arthritisClin Exp Rheumatol2008215 Suppl 31S179S185
   Google Scholar
• ChiaravallotiAJStroberBEThe use of self-administered subcutaneous methotrexate for the treatment of psoriasisJ Drugs Dermatol201413892993125116970
   PubMed Web of Science ®Google Scholar
• JundtJWBrowneBAFioccoGPSteeleADMockDA comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosingJ Rheumatol19932011184518498308768
   PubMed Web of Science ®Google Scholar
• VisserKvan der HeijdeDOptimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literatureAnn Rheum Dis20096871094109919033290
   PubMed Web of Science ®Google Scholar
• BalisFMirroJJrReamanGHPharmacokinetics of subcutaneous methotrexateJ Clin Oncol1988612188218863199171
   PubMed Web of Science ®Google Scholar
• TianHCronsteinBNUnderstanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritisBull NYU Hosp Jt Dis200765316817317922664
   PubMedGoogle Scholar
• HoekstraMHaagsmaCNeefCProostJKnuifAvan de LaarMBioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritisJ Rheumatol200431464564815088287
   PubMed Web of Science ®Google Scholar
• TukováJChládekJNemcováDChládkováJDolezalováPMethotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritisClin Exp Rheumatol20092761047105320149329
   PubMed Web of Science ®Google Scholar
• SchiffMHJaffeJSFreundlichBHead-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administrationAnn Rheum Dis20147381549155124728329
   PubMed Web of Science ®Google Scholar
• BraunJKästnerPFlaxenbergPMC-MTX.6/RH Study GroupComparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trialArthritis Rheum2008581738118163521
   PubMed Web of Science ®Google Scholar
• HameedBJonesHSubcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritisInt J Rheum Dis2010134e83e8421199461
   PubMed Web of Science ®Google Scholar
• In brief: otrexup – a single-use auto-injector formulation of methotrexateMed Lett Drugs Ther20145614392824691150
   PubMed Web of Science ®Google Scholar
• medac GmbHBioavailability in patient with psoriasis: Metoject pre-filled pen ClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2014 [updated March 13, 2015]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02097173?term=NCT02097173&rank=1. NLM identifier: NCT02097173Accessed January 2, 2015
   Google Scholar
• Metoject [homepage on the Internet]Medac Pharma, Inc Available at: http://www.metoject.comAccessed January 29, 2015
   Google Scholar
• Rasuvo [drug label]Chicago, ILMedac Pharma, Inc2014
   Google Scholar
• PichlmeierUHeuerKSubcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexateClin Exp Rheumatol201432456357124983446
   PubMed Web of Science ®Google Scholar
• KromannCLage-HansenPKoefoedMJemecGBDoes switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects?J Dermatolog Treat Epup6172014
   Web of Science ®Google Scholar
• BormanPDemirGKaygısızFOkumuşMLETTER TO THE EDITOR Subcutaneous (SC) Methotrexate (MTX) is Better and Well-Tolerable than Oral MTX in Rheumatoid Arthritis Patients, Switched from Oral to SC Administration Due to Gastrointestinal Side EffectsOpen Rheumatol J20148181925232363
   PubMedGoogle Scholar
• VanscottEJAuerbachRWeinsteinGDParenteral methotrexate in psoriasisArch Dermatol19648955055614107621
   PubMedGoogle Scholar
• FryLThe treatment of psoriasis with parenteral methotrexateBr J Dermatol19667852822885937350
   PubMed Web of Science ®Google Scholar
• NewmanMAuerbachRFeinerHThe role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatmentArch Dermatol19891259121812242774597
   PubMedGoogle Scholar
• StriesowFBrandtAPreference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulationTher Adv Musculoskelet Dis2012413922870490
   PubMedGoogle Scholar
• DemaryWSchwenkeHRockwitzKSubcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experiencePatient Prefer Adherence201481061107125125973
   PubMed Web of Science ®Google Scholar
• FreundlichBKivitzAJaffeJNearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitationsJ Clin Rheumatol201420525626025036562
   PubMed Web of Science ®Google Scholar
• PuigLMethotrexate: new therapeutic approachesActas Dermosifiliogr2014105658358923434058
   PubMedGoogle Scholar
• CrespoCBrosaMGalvánJPharmacoeconomic analysis of Metoject(®) in the treatment of rheumatoid arthritis in SpainReumatol Clin201064203211 Spanish21794714
   PubMedGoogle Scholar
• FitzpatrickRScottDKearyICost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexateClin Rheumatol201332111605161223835658
   PubMed Web of Science ®Google Scholar
• MontaudiéHSbidianEPaulCMethotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicityJ Eur Acad Dermatol Venereol201125Suppl 21218
   PubMed Web of Science ®Google Scholar